

1 19
agent
44. (Amended) A method of delivering a therapeutic ^{agent} comprising the step of administering a therapeutically effective amount of a therapeutic composition of claim ~~18~~ *19*.

20
C2
46. (Amended) A method of delivering a therapeutic agent comprising the steps of:
combining a cyclodextrin copolymer of claims ~~1, 8, 9, or 10~~ *6, 7, 8* with a therapeutic agent to form a mixture; and
allowing said mixture to self-assemble to form an associated composition; and
administering a therapeutically effective amount of said associated composition to a subject in need of said therapeutic agent.

C3 21
48. (Amended) A linear cyclodextrin copolymer of claim ~~1, 8, 9, or 10~~ *6, 7, 8* wherein said linear cyclodextrin copolymer is water soluble.

C4 23
50. (Amended) A method of delivering a therapeutic ^{agent} comprising the step of administering a therapeutically effective amount of a therapeutic composition of claim ~~49~~ *23*.

D 25
C5
56. (New) A therapeutic composition of claim ~~49~~ *22* ^{further comprising} wherein at least one ligand is bound to the linear cyclodextrin copolymer.

D 26
57. (New) A method of delivering a therapeutic ^{agent} comprising the step of administering a therapeutically effective amount of a therapeutic composition of claim ~~56~~ *25*.

REMARKS

Claims 1-3, 6-10, 18, 24-27, 30-34, 44, 46, 48-50, 56 and 57 are pending in this application. Claims 47 and 52-55 have been canceled. Claims 52-55 are cancelled due to a duplicate numbering of two claims as claim 52. Claim 47 is cancelled as the Examiner indicated that it was of the same scope as claim 1. Claims 46 and 48 have been amended to correct dependencies in view of the